Evaluation of the effect of curcumin in the prevention of vancomycin-induced nephrotoxicity in patients hospitalized in the intensive care unit

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240501061620N1

Enrollment

Registered

2024-05-08

Start date

2024-06-04

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kidney failure. Acute kidney failure, unspecified

Interventions

Intervention 1: Intervention group: Patients will receive curcumin tablet (Dineh Iran Company), 500 mg three times a day for 7 days. Intervention 2: Control group: Patients will receive placebo tablet

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients aged 18-65, receiving vancomycin Creatinine clearance > 45 ml/min

Exclusion criteria

Exclusion criteria: Proteinuria and/or hematuria, acute kidney injury or any underlying renal disorder Septic shock Sever liver disease Sever and active bleeding Receiving any other nephrotoxic drug Receiving anticoagulant drugs at therapeutic doses or receiving warfarin Receiving antioxidant supplements

Design outcomes

Primary

Measure	Time frame
Serum Creatinine. Timepoint: At baseline and 2, 4, 6, and 8 days after initiation of intervention. Method of measurement: Spectrophotometry.;Blood Urea Nitrogen. Timepoint: At baseline and 2, 4, 6, and 8 days after initiation of intervention. Method of measurement: Spectrophotometry.;Creatinine Clearance. Timepoint: At baseline and 2, 4, 6, and 8 days after initiation of intervention. Method of measurement: Modification of Diet in Renal Disease (MDRD) Formula.;24-hour Urine Output. Timepoint: Days 1 to 7. Method of measurement: Urine bag.;The number of patients with acute kidney injury. Timepoint: End of intervention. Method of measurement: Counting.;Sequential Organ Failure Assessment (SOFA). Timepoint: At baseline and end of intervention. Method of measurement: SOFA table.	—

Measure

Time frame

Serum Creatinine. Timepoint: At baseline and 2, 4, 6, and 8 days after initiation of intervention. Method of measurement: Spectrophotometry.;Blood Urea Nitrogen. Timepoint: At baseline and 2, 4, 6, and 8 days after initiation of intervention. Method of measurement: Spectrophotometry.;Creatinine Clearance. Timepoint: At baseline and 2, 4, 6, and 8 days after initiation of intervention. Method of measurement: Modification of Diet in Renal Disease (MDRD) Formula.;24-hour Urine Output. Timepoint: Days 1 to 7. Method of measurement: Urine bag.;The number of patients with acute kidney injury. Timepoint: End of intervention. Method of measurement: Counting.;Sequential Organ Failure Assessment (SOFA). Timepoint: At baseline and end of intervention. Method of measurement: SOFA table.

—

Secondary

Measure	Time frame
Mortality rate of patients. Timepoint: After intervention until discharge from ICU. Method of measurement: Counting.;Length of stay in the ICU. Timepoint: At discharge day from ICU. Method of measurement: Counting.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSolaleh Rezanavaz Gheshlagh

Semnan University of Medical Sciences

solaleh.rezanavaz2017@gmail.com+98 23 3142 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026